BiotechHow drugs got on TV, uBiome’s last days, & and the (possible) biotech future of an ex-Goldman exec By Damian Garde Sept. 5, 2019 Reprints Alex Hogan/STAT The Readout for September 05, 2019 Unlock this article by subscribing to STAT+ and enjoy your first 30 days free! GET STARTED Log In About the Author Reprints Damian Garde National Biotech Reporter Damian Garde covers biotech, is a co-writer of The Readout newsletter, and a co-host of "The Readout LOUD" podcast. [email protected] @damiangarde
Business Bob Herman STAT Plus: Wary of changes to Medicare Advantage, health insurers put up a fight — and exaggerate the stakes
Health Tech Brittany Trang and Casey Ross STAT Plus: ‘We’re getting much more aggressive’: Microsoft’s Nuance adds GPT-4 AI to its medical note-taking tool
A STAT Investigation Casey Ross and Bob Herman STAT Plus: Denied by AI: How Medicare Advantage plans use algorithms to cut off care for seniors in need
Biotech Adam Feuerstein, Damian Garde and Allison DeAngelis STAT Plus: SVB, biotech’s bank of choice, just failed. It could have ripple effects
